FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321764716> ?p ?o ?g. }

• W4321764716 endingPage "2757" @default.
• W4321764716 startingPage "2746" @default.
• W4321764716 abstract "The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in patients with MM after auto-HSCT using CIBMTR registry data. Adult patients with MM who underwent first auto-HSCT in the United States with melphalan conditioning regimen from 2011 to 2018 and received maintenance therapy were included (n = 3948). At a median follow-up of 37 months, 175 (4%) patients developed SPM, including 112 (64%) solid, 36 (20%) myeloid, 24 (14%) SHM, not otherwise specified, and 3 (2%) lymphoid malignancies. Multivariate analysis demonstrated that SPM and SHM were associated with an inferior PFS (hazard ratio [HR] 2.62, P < .001 and HR 5.01, P < .001, respectively) and OS (HR 3.85, P < .001 and HR 8.13, P < .001, respectively). In patients who developed SPM and SHM, MM remained the most frequent primary cause of death (42% vs 30% and 53% vs 18%, respectively). We conclude the development of SPM and SHM leads to a poor survival in patients with MM and is an important survivorship challenge. Given the median survival for MM continues to improve, continued vigilance is needed to assess the risks of SPM and SHM with maintenance therapy post-auto-HSCT." @default.
• W4321764716 created "2023-02-25" @default.
• W4321764716 creator A5000584189 @default.
• W4321764716 creator A5001668616 @default.
• W4321764716 creator A5004066032 @default.
• W4321764716 creator A5004466299 @default.
• W4321764716 creator A5008366988 @default.
• W4321764716 creator A5009378735 @default.
• W4321764716 creator A5010023051 @default.
• W4321764716 creator A5012489403 @default.
• W4321764716 creator A5015342719 @default.
• W4321764716 creator A5017327825 @default.
• W4321764716 creator A5018521931 @default.
• W4321764716 creator A5019494133 @default.
• W4321764716 creator A5020872528 @default.
• W4321764716 creator A5021941594 @default.
• W4321764716 creator A5022331310 @default.
• W4321764716 creator A5022845873 @default.
• W4321764716 creator A5023475751 @default.
• W4321764716 creator A5023628069 @default.
• W4321764716 creator A5026574827 @default.
• W4321764716 creator A5026706680 @default.
• W4321764716 creator A5029237145 @default.
• W4321764716 creator A5029295767 @default.
• W4321764716 creator A5036605555 @default.
• W4321764716 creator A5036651522 @default.
• W4321764716 creator A5039067043 @default.
• W4321764716 creator A5042992484 @default.
• W4321764716 creator A5043016347 @default.
• W4321764716 creator A5043033429 @default.
• W4321764716 creator A5053253072 @default.
• W4321764716 creator A5053904944 @default.
• W4321764716 creator A5055922112 @default.
• W4321764716 creator A5056755045 @default.
• W4321764716 creator A5057643441 @default.
• W4321764716 creator A5062691289 @default.
• W4321764716 creator A5065085606 @default.
• W4321764716 creator A5067531512 @default.
• W4321764716 creator A5069685528 @default.
• W4321764716 creator A5074515375 @default.
• W4321764716 creator A5075529211 @default.
• W4321764716 creator A5077959781 @default.
• W4321764716 creator A5086380393 @default.
• W4321764716 creator A5090669888 @default.
• W4321764716 date "2023-06-15" @default.
• W4321764716 modified "2023-10-03" @default.
• W4321764716 title "Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis" @default.
• W4321764716 cites W2067725825 @default.
• W4321764716 cites W2080030013 @default.
• W4321764716 cites W2083357419 @default.
• W4321764716 cites W2102591890 @default.
• W4321764716 cites W2116749573 @default.
• W4321764716 cites W2125721471 @default.
• W4321764716 cites W2128084036 @default.
• W4321764716 cites W2143425592 @default.
• W4321764716 cites W2167021542 @default.
• W4321764716 cites W2264688301 @default.
• W4321764716 cites W2519531170 @default.
• W4321764716 cites W2520902851 @default.
• W4321764716 cites W2550414527 @default.
• W4321764716 cites W2560592054 @default.
• W4321764716 cites W2737964630 @default.
• W4321764716 cites W2783620222 @default.
• W4321764716 cites W2784286628 @default.
• W4321764716 cites W2807969969 @default.
• W4321764716 cites W2878788161 @default.
• W4321764716 cites W2883543196 @default.
• W4321764716 cites W2883855193 @default.
• W4321764716 cites W2901409352 @default.
• W4321764716 cites W2946374758 @default.
• W4321764716 cites W3006419152 @default.
• W4321764716 cites W3017057237 @default.
• W4321764716 cites W3119106861 @default.
• W4321764716 cites W3137800576 @default.
• W4321764716 cites W3145716452 @default.
• W4321764716 cites W3160658638 @default.
• W4321764716 cites W3166544635 @default.
• W4321764716 cites W3195493284 @default.
• W4321764716 cites W4210777755 @default.
• W4321764716 cites W4226073613 @default.
• W4321764716 cites W4281628749 @default.
• W4321764716 cites W4281862530 @default.
• W4321764716 cites W4307647274 @default.
• W4321764716 doi "https://doi.org/10.1182/bloodadvances.2022009138" @default.
• W4321764716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36827681" @default.
• W4321764716 hasPublicationYear "2023" @default.
• W4321764716 type Work @default.
• W4321764716 citedByCount "8" @default.
• W4321764716 countsByYear W43217647162023 @default.
• W4321764716 crossrefType "journal-article" @default.
• W4321764716 hasAuthorship W4321764716A5000584189 @default.
• W4321764716 hasAuthorship W4321764716A5001668616 @default.
• W4321764716 hasAuthorship W4321764716A5004066032 @default.
• W4321764716 hasAuthorship W4321764716A5004466299 @default.
• W4321764716 hasAuthorship W4321764716A5008366988 @default.
• W4321764716 hasAuthorship W4321764716A5009378735 @default.
• W4321764716 hasAuthorship W4321764716A5010023051 @default.
• W4321764716 hasAuthorship W4321764716A5012489403 @default.

• next